Similar companies
Income Statement (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Gross Profit | -4.8M | 153.3% |
| Cost of Revenue | 4.8M | 12.2% |
| Operating expense | 11M | 3.1% |
| Net Income | -11M | 23.7% |
| EBITDA | -11M | 3.5% |
Balance Sheet (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Total Assets | 97M | 7% |
| Total Liabilities | 11M | 0.6% |
| Total Equity | 86M | 8% |
| Shares Outstanding | 181M | 13.6% |
Cash Flow (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Cash from operations | -8.4M | 7.5% |
| Cash from investing | -8.9M | 0% |
| Cash from financing | 14M | 0% |
EPS
Financial Highlights for Citius Pharmaceuticals in Q2 '24
Gross Profit stood at -4.8M, marking a -153.3% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 4.8M, a 12.2% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 11M, showing a -3.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -11M, showing a -23.7% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -11M, showing a 3.5% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Citius Pharmaceuticals faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
